• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Namekit, test, alpha-fetoprotein for neural tube defects
Generic Namechemiluminescent immunoassay for in vitro diagnostic quantitation of afp in maternal and amniotic fluid
PMA NumberP980041
Supplement NumberS001
Date Received06/18/2002
Decision Date10/01/2002
Product Code
LOK[ Registered Establishments with LOK ]
Advisory Committee Immunology
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications - component
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for expanding the use of the afp immunoassay on the access 2 analyzer. The device, as modified, will be marketed under the tradename access afp immunoassay system and is indicated for the quantitative determination of alpha-fetoprotein (afp) in: 1) human serum, as an aid in the management of patients with non-seminomatous testicular cancer. 2) maternal serum and amniotic fluid at 15 to 20 weeks gestation, to aid in the detection of fetal open neural tube defects (ontd). Test results, when used in conjunction with ultrasonography, are safe and effective aids in the detection of fetal ontd. The assay is intended for used in conjunction with other diagnostic tools such as ultrasound and amniography.